Xuanzhu Biopharmaceutical Co., Ltd.

2 marketed · 4 in Phase 3

Quick facts

Marketed products

Anelazol Sodium Enteric-coated Tablets · Immunology / Inflammatory diseases
Anelazol sodium is an anti-inflammatory agent that inhibits leukotriene synthesis and reduces inflammatory mediator production.
XZP-5610 Tablet for "Part C2"

Phase 3 pipeline

Placebo + Letrozole/Anastrozole · Oncology
Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.
XZP-3287+Fulvestrant · Oncology
XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor.
XZP-3287+ Letrozole/Anastrozole · Oncology
XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.
XZP-3621

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Xuanzhu Biopharmaceutical Co., Ltd.

What are Xuanzhu Biopharmaceutical Co., Ltd.'s marketed drugs?

Top marketed products include Anelazol Sodium Enteric-coated Tablets, XZP-5610 Tablet for "Part C2".

What is Xuanzhu Biopharmaceutical Co., Ltd.'s pipeline?

Xuanzhu Biopharmaceutical Co., Ltd. has 4 drugs in Phase 3, 0 in Phase 2, 11 in Phase 1. Late-stage candidates include Placebo + Letrozole/Anastrozole, XZP-3287+Fulvestrant, XZP-3287+ Letrozole/Anastrozole, XZP-3621.

Anelazol Sodium Enteric-coated Tablets · Immunology / Inflammatory diseases
XZP-5610 Tablet for "Part C2"
Sector hub: All tracked pharma companies